司柏利单抗改善泛发性脓疱型银屑病患者报告结局:Effisayil 1研究结果
Effisayil 1研究将53例泛发性脓疱型银屑病(GPP)急性发作患者按2:1随机接受单次静脉注射司柏利单抗900 mg或安慰剂,随访12周。司柏利单抗组在治疗1周内疼痛视觉模拟量表、FACIT-疲劳量表、皮肤病生活质量指数和银屑病症状量表均较基线改善,并达到最小临床重要差异,改善持续至12周。
要点
- 司柏利单抗组1周内疼痛VAS较基线改善(中位数-21.3),并持续至12周。
- 司柏利单抗组1周内FACIT-疲劳量表较基线改善(中位数7.0),并持续至12周。
- 司柏利单抗组1周内DLQI和PSS较基线改善,并达到最小临床重要差异。
核心结论
- 接受司柏利单抗治疗的GPP急性发作患者在1周内患者报告结局改善并达到最小临床重要差异,改善持续12周。
研究设计与样本
- Effisayil 1研究为随机对照研究,53例GPP急性发作患者按2:1随机接受单次静脉注射司柏利单抗900 mg或安慰剂,随访12周。
主要发现
- 司柏利单抗组疼痛VAS较基线改善中位数-21.3(Q1,Q3:-55.3,-3.1)。
- 司柏利单抗组FACIT-疲劳量表较基线改善中位数7.0(Q1,Q3:1.0,20.0)。
- 司柏利单抗组DLQI较基线改善中位数-2.5(Q1,Q3:-8.0,1.0)。
- 司柏利单抗组PSS较基线改善中位数-4.0(Q1,Q3:-7.0,0.0)。
- 安慰剂组在第1周接受开放标签司柏利单抗后患者报告结局改善并达到最小临床重要差异。
关键数值与推荐
- 最小临床重要差异(MCID)在研究中有定义。
- 所有数据均作描述性报告。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Generalized pustular psoriasis (GPP) is a rare inflammatory skin disease with a considerable clinical burden. In the Effisayil™ 1 study, spesolimab, an anti-interleukin-36 receptor monoclonal antibody, demonstrated efficacy in treating GPP flares. OBJECTIVES: To evaluate patient-reported outcomes (PROs) of patients with GPP who were treated with intravenous (IV) spesolimab 900 mg in the Effisayil™ 1 study. METHODS: Fifty-three patients presenting with a GPP flare were randomized (2:1) to receive a single dose of IV spesolimab 900 mg or placebo and were followed for 12 weeks. Four PROs (pain visual analogue scale [pain VAS]; Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-Fatigue]; Dermatology Life Quality Index [DLQI]; and Psoriasis Symptom Scale [PSS]) were assessed throughout the 12-week study. Minimal clinically important differences (MCIDs) were defined. All data are reported descriptively. RESULTS: In patients who received spesolimab, improvements from baseline (median [Q1, Q3]) were observed in pain VAS (-21.3 [-55.3, -3.1]), FACIT-Fatigue (7.0 [1.0, 20.0]), DLQI (-2.5 [-8.0, 1.0]) and PSS (-4.0 [-7.0, 0.0]) within 1 week of treatment. These improvements were sustained over 12 weeks and corresponded to the achievement of MCIDs at Week 1, which were also sustained over 12 weeks. Patients in the placebo arm experienced improvements in PROs and achievement of MCIDs after receipt of open-label spesolimab at Week 1. CONCLUSIONS: Patients with a GPP flare treated with spesolimab achieved improvements in PROs by Week 1, which were sustained for 12 weeks, and achieved MCIDs as early as Week 1.
引用
- Navarini AA, Prinz JC, Morita A, et al. Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 study. J Eur Acad Dermatol Venereol. 2023. PMID: 36527385. doi:10.1111/jdv.18820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。